引用本文: | 朱彧,何学敏,陈明,盛云,张俊富,陆伟.降脂方对非酒精性脂肪肝的治疗效果及其对患者肠道菌群和代谢的影响[J].中国现代应用药学,2022,39(17):2250-2256. |
| ZHU Yu,HE Xuemin,CHEN Ming,SHENG Yun,ZHANG Junfu,LU Wei.Therapeutic Effect of Jiangzhi Decoction on Non-alcoholic Fatty Liver Disease and Its Effect on Intestinal Flora and Metabolism for Patient[J].Chin J Mod Appl Pharm(中国现代应用药学),2022,39(17):2250-2256. |
|
本文已被:浏览 1269次 下载 583次 |
码上扫一扫! |
|
降脂方对非酒精性脂肪肝的治疗效果及其对患者肠道菌群和代谢的影响 |
朱彧1, 何学敏2, 陈明3, 盛云2, 张俊富2, 陆伟2
|
1.天津市第三中心医院检验科, 天津 300350;2.天津市第一医院, 天津市肝病研究所, 天津 300231;3.天津市南开医院, 天津 300100
|
|
摘要: |
目的 考察降脂方对非酒精性脂肪肝(non-alcoholic fatty liver disease,NAFLD)的治疗效果及其对肠道菌群和代谢的影响。方法 选取NAFLD患者13例作为患者组,选取体检健康志愿者15名作为健康组,患者组服用降脂方3月后,通过患者糖脂代谢、胰岛和肝脏功能的变化考察降脂方的治疗效果,通过16S rRNA测序技术考察粪便标本肠道菌群丰度的变化,代谢组学技术考察粪便标本代谢产物含量的变化。结果 NAFLD患者肠道菌群构成发生较大变化,多样性显著下降(P<0.05),巨单胞菌属占优势,服药3月后,降脂方可显著降低NAFLD患者肝脏硬度并改善其糖脂代谢、胰岛和肝脏功能,肠道中布劳特氏菌属相对丰度显著上调(P<0.05),栖粪杆菌属、布劳特氏菌属和拟杆菌属较占优势。与降脂方治疗前组相比,治疗后组患者粪便中代谢产物68个显著上调,43个显著下调(P均<0.05),嘧啶代谢等功能具有统计学意义(P<0.05)。结论 降脂方对NAFLD具有较好的治疗效果,可调控NAFLD患者肠道菌群和代谢功能。 |
关键词: 降脂方 非酒精性脂肪肝 肠道菌群 代谢功能 |
DOI:10.13748/j.cnki.issn1007-7693.2022.17.013 |
分类号:R969.1 |
基金项目:天津市卫生和计划生育委员会中医中西医结合科研课题重点项目(2017084) |
|
Therapeutic Effect of Jiangzhi Decoction on Non-alcoholic Fatty Liver Disease and Its Effect on Intestinal Flora and Metabolism for Patient |
ZHU Yu1, HE Xuemin2, CHEN Ming3, SHENG Yun2, ZHANG Junfu2, LU Wei2
|
1.Department of Clinical Laboratory, Tianjin Third Central Hospital, Tianjin 300350, China;2.Tianjin First Hospital, Tianjin Institute of Hepatology, Tianjin 300231, China;3.Tianjin Nankai Hospital, Tianjin 300100, China
|
Abstract: |
OBJECTIVE To investigate the therapeutic effect of Jiangzhi Decoction on non-alcoholic fatty liver disease(NAFLD) and its effect on gut microbiota and metabolism. METHODS The 13 NAFLD patients were selected as the patient group and 15 healthy volunteers were selected as the healthy group. The patient group were treated with Jiangzhi Decoction and explored the therapeutic effect via the mechanism of plasma glucose and lipoid, function of islets of langerhans and liver after 3 months, the changes of gut microbiota abundance in fecal samples were determined by 16S rRNA sequencing technology and the changes of metabolites in fecal samples were determined by metabonomics technology. RESULTS There was a big change on gut microbiota structure in NAFLD patients with a significant decreased diversity(P<0.05) and Megamonas was dominant, Jiangzhi Decoction could significantly decrease NAFLD patients' liver hardness and improve the mechanism of plasma glucose and lipoid, function of islets of langerhans and liver with 3 months treatment. The relative abundance of Blautia in the gut was significantly increased(P<0.05) and Faecalibacterium, Blautia and Bacteroides were dominant. Compared with the pre-treatment group, the fecal metabolites of patients in the post-treatment group were significantly up-regulated by 68, significantly down-regulated by 43(P all<0.05). There were significant differences in pyrimidine metabolism function and so on(P<0.05). CONCLUSION Jiangzhi Decoction has good therapeutic effect on NAFLD and can regulate intestinal flora and metabolic function in patients with NAFLD. |
Key words: Jiangzhi Decoction non-alcoholic fatty liver disease gut microbiota metabolic function |